Oramed Pharmaceuticals (NASDAQ:ORMP) Issues Quarterly Earnings Results

Oramed Pharmaceuticals (NASDAQ:ORMP) announced its quarterly earnings results on Tuesday. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, FiscalAI reports.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ:ORMP traded up $0.04 during trading on Tuesday, hitting $4.33. The company’s stock had a trading volume of 285,693 shares, compared to its average volume of 188,772. Oramed Pharmaceuticals has a fifty-two week low of $1.98 and a fifty-two week high of $5.01. The stock’s 50-day moving average price is $3.74 and its two-hundred day moving average price is $3.28. The company has a market capitalization of $175.15 million, a PE ratio of 2.91 and a beta of 1.27.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Oramed Pharmaceuticals in a report on Friday, March 27th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ORMP. Kathmere Capital Management LLC acquired a new position in Oramed Pharmaceuticals in the first quarter worth about $51,000. OMERS ADMINISTRATION Corp acquired a new position in Oramed Pharmaceuticals in the first quarter worth about $63,000. Redwood Family Wealth LLC acquired a new position in Oramed Pharmaceuticals in the fourth quarter worth about $66,000. XTX Topco Ltd grew its stake in Oramed Pharmaceuticals by 59.9% in the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 14,297 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new position in Oramed Pharmaceuticals in the fourth quarter worth about $119,000. 12.73% of the stock is currently owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.